INBP — Integrated Biopharma Share Price
0.000.00%
Last trade - 00:00- $9.09m
- $6.63m
- $50.32m
- 100
- 98
- 59
- 98
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.46 | ||
| Price to Tang. Book | 0.46 | ||
| Price to Free Cashflow | 5.23 | ||
| Price to Sales | 0.17 | ||
| EV to EBITDA | 3.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.21% | ||
| Return on Equity | 4.85% | ||
| Operating Margin | 2.78% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 52.77 | 63.56 | 56.25 | 50.67 | 50.32 | n/a | n/a | 0.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +131.11 | +63.56 | -44.38 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Integrated BioPharma, Inc. is engaged in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials.
Directors
- E. Gerald Kay CHM (78)
- Christina Kay CCE (44)
- Riva Sheppard CCE (47)
- Dina Masi CFO (52)
- Carl DeSantis DRC (74)
- Eric Friedman DRC (74)
- William Milmoe DRC (72)
- Robert Canarick IND (63)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 31st, 1995
- Public Since
- October 30th, 1996
- No. of Shareholders
- 73
- No. of Employees
- 147
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 30,300,720
- Address
- 225 Long Ave Ste 15, HILLSIDE, 07205-2356
- Web
- https://ir.ibiopharma.com
- Phone
- +1 9739260816
- Contact
- Dina Masi
- Auditors
- Marcum LLP
Upcoming Events for INBP
Q4 2025 Integrated Biopharma Inc Earnings Release
Similar to INBP
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Integrated Biopharma share price?
As of Today at 21:20 UTC, shares in Integrated Biopharma are trading at $0.30. This share price information is delayed by 15 minutes.
How has the Integrated Biopharma share price performed this year?
Shares in Integrated Biopharma last closed at $0.30 and the price had moved by +39.53% over the past 365 days. In terms of relative price strength the Integrated Biopharma share price has outperformed the S&P500 Index by +30.36% over the past year.
What are the analyst and broker recommendations for Integrated Biopharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Integrated Biopharma dividend yield?
Integrated Biopharma does not currently pay a dividend.
Does Integrated Biopharma pay a dividend?
Integrated Biopharma does not currently pay a dividend.
When does Integrated Biopharma next pay dividends?
Integrated Biopharma does not currently pay a dividend.
How do I buy Integrated Biopharma shares?
To buy shares in Integrated Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Integrated Biopharma?
As of the previous close price of $0.30, shares in Integrated Biopharma had a market capitalisation of $9.09m.
Where are Integrated Biopharma shares listed?
Here are the trading details for Integrated Biopharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: INBP
What kind of share is Integrated Biopharma?
Based on an overall assessment of its quality, value and momentum Integrated Biopharma is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Integrated Biopharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Integrated Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Integrated Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +8.77%.
As of the last closing price of $0.30, shares in Integrated Biopharma were trading +9.53% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Integrated Biopharma PE Ratio?
The Integrated Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Integrated Biopharma?
Integrated Biopharma's management team is headed by:
- E. Gerald Kay - CHM
- Christina Kay - CCE
- Riva Sheppard - CCE
- Dina Masi - CFO
- Carl DeSantis - DRC
- Eric Friedman - DRC
- William Milmoe - DRC
- Robert Canarick - IND